Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study.
Yu-Nan HuangWen-Ling LiaoJing-Yang HuangYu-Jung LinShun-Fa YangChieh-Chen HuangChung-Hsing WangPen-Hua SuPublished in: Diabetes, obesity & metabolism (2024)
In this large observational study, GLP-1 RAs showed long-term protective effects on cardiovascular health, renal outcomes and adverse events in individuals with obesity and without T2D. Our findings suggest that GLP-1 RAs may offer a comprehensive approach to managing obesity and its related comorbidities, potentially improving overall health and survival in this population.